Vivos Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

First medicare-accepted oral appliance treatment for all severities of obstructive sleep apnea in adults first medicare-accepted oral appliance treatment for all severities of obstructive sleep apnea in adults

Positive business momentum and sales pipeline growth following fda 510(k) clearance of vivos' proprietary oral medical devices to treat severe obstructive sleep apnea

Littleton, colo., march 28, 2024 (globe newswire) -- vivos therapeutics, inc. (“vivos” or the “company”) (nasdaq: vvos), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (osa in adults)), today announced it plans to release its fourth quarter and full year 2023 financial results after market close today, thursday, march 28, 2024.

United healthcare updated medical policy favoring oral appliance therapies and recent recalls of many resmed and philips respironics' cpap devices create significant revenue opportunities for vivos devices united healthcare updated medical policy favoring oral appliance therapies and recent recalls of many resmed and philips respironics' cpap devices create significant revenue opportunities for vivos devices

New dentist inquiries jumped 600% and signed dentist enrollment contracts up 38% sequentially over q3 care oral medical device unit orders increased 26% following fda clearance littleton, colo., jan. 08, 2024 (globe newswire) -- vivos therapeutics, inc. (the “company” or “vivos”) (nasdaq:vvos), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (osa)), is pleased to announce that vivos is seeing positive preliminary metrics following its november 28, 2023 announcement regarding fda 510(k) clearance of its care oral medical devices to treat severe osa.

Vivos Therapeutics (NASDAQ:VVOS) CEO Kirk Huntsman expects to see more medical and dental professionals recommending its oral medical devices for obstructive sleep apnea (OSA) after they secured Medicare reimbursement approval.   The company announced earlier this week that its CARE oral medical devices, an alternative to continuous positive airway pressure (CPAP) for patients with OSA, have been approved for Medicare reimbursement by the Centers for Medicare and Medicaid Services (CMS).

Vivos Therapeutics (NASDAQ:VVOS) announced that its CARE oral medical devices for obstructive sleep apnea (OSA) have been approved for Medicare reimbursement. The company said this milestone achievement will allow millions of Medicare beneficiaries coverage and reimbursement for allowable charges billable to Medicare.

Vivos Therapeutics (NASDAQ:VVOS) is on track to become cash flow positive by the end of 2024, its CEO revealed in its latest financial update. “Based on our progress to date and our revenue growth efforts for 2024, we continue to anticipate becoming cash flow positive from operations by the end of this year,” CEO Kirk Huntsman told shareholders.

Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript

LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults)), today announced it plans to release its fourth quarter and full year 2023 financial results after market close today, Thursday, March 28, 2024.

Vivos Therapeutics (NASDAQ:VVOS) announced that it has entered into a definitive agreement to immediately exercise an outstanding stock purchase warrant held by an institutional investor to purchase an aggregate of 980,393 shares for approximate proceeds of $4 million. The net proceeds will be used by the medical device company specializing in treatments for sleep-related breathing disorders for general corporate purposes.

Vivos Therapeutics (NASDAQ:VVOS) is well-positioned to increase the adoption of its oral medical devices for the treatment of severe obstructive sleep apnea as patients seek alternatives to continuous positive airway pressure (CPAP).  The company's Vivos CARE oral appliance in November 2023 received US Food and Drug Administration (FDA) approval to treat moderate to severe obstructive sleep apnea in adults along with positive airway pressure and/or myofunctional therapy, as required.

Vivos Therapeutics (NASDAQ:VVOS) told investors it has experienced a surge in interest in the wake of the FDA 510(k) clearance from the US Food and Drug Administration (FDA) for its CARE (Complete Airway Repositioning and/or Expansion) oral medical devices targeting severe obstructive sleep apnea (OSA). The medical technology firm said the groundbreaking clearance, granted on November 28, 2023, marks the first time the FDA has approved an oral appliance for treating moderate and severe OSA in adults, aged 18 and older, complemented by positive airway pressure (PAP) and/or myofunctional therapy.

Vivos Therapeutics (NASDAQ:VVOS) announced that it will be hosting a women-led airway health-focused event at the Vivos Institute in Denver, Colorado, on February 1 and 2, 2024. The company said the event, “Empowering Women to Champion Airway,” will bring together prominent women in the medical and dental fields to drive collaboration around airway health.

Every so often, a move occurs in the stock market that can best be described as a 'black swan.' That is to say, a move that occurs in an individual stock that is exceedingly rare from a probabilistic standpoint.